Beranda › Adenokarsinoma Esofagus › Massachusetts
Uji klinis Adenokarsinoma Esofagus di Massachusetts
13 studi untuk Adenokarsinoma Esofagus mencari peserta di lokasi di Massachusetts.
Kota di Massachusetts
Teks studi resmi (Bahasa Inggris)
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
- Boston Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
- Dana-Farber Cancer Institute at Boston Medical Center - Brighton, Brighton
- dan 4 lainnya
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT05677490A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
- Dana-Farber Cancer Institute - Chestnut Hill, Newton
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT07090499Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- Dana-Farber Cancer Institute, Boston
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT06324357Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas
- Massachusetts General Hospital, Boston
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 21 Sep 2026 · NCT07546812Surveillance vs. Endoscopic Therapy for Barrett's Esophagus With Low-grade Dysplasia
- Beth Israel Deaconess Medical Center, Boston
Menerima peserta
Usia 18 hingga 89 · Semua jenis kelamin · Diperbarui 11 Sep 2026 · NCT05753748Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
- Research Site, Boston
- Research Site, Burlington
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Sep 2026 · NCT07431281A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers
- Dana-Farber Cancer Institute, Boston
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 27 Agu 2026 · NCT07544589A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
- Normunity Investigational Site, Boston
- Normunity Investigational Site, Boston
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Agu 2026 · NCT07182149A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- Massachusetts General Hospital, Boston
- Brigham & Women's Hospital, Boston
- Beth Israel Deaconess Medical Center,East Campus Research Pharmacy, Boston
- dan 3 lainnya
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 6 Jul 2026 · NCT04389632Clonal Hematopoiesis Chemotherapy and Radiation Effects Study
- Dana-Farber Cancer Institute, Boston
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Jun 2026 · NCT07675967First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
- Research Site, Boston
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 12 Jun 2026 · NCT07284186Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
- I-Mab Site 1002, Boston
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 14 Mei 2026 · NCT07432295Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
- Mass General Hospital, Boston
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Mar 2026 · NCT04900818Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.